- Lyra Therapeutics Inc (NASDAQ:LYRA) has announced a private placement of approximately $100.5 million.
- The Company has offered 18.8 million common shares at $4.22 per share and pre-funded warrants to purchase an aggregate of 5 million shares with an exercise price of $0.001 per share, at $4.219 per share.
- Each pre-funded warrant will be exercisable immediately.
- Related: Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients.
- The offering will close by April 12.
- LYR-210 and LYR-220 are designed to be administered in non-invasive, in-office procedures and deliver up to six months of continuous anti-inflammatory medication to the sinonasal passages of CRS patients.
- As of December 31, 2021, cash & cash equivalents were $45.7 million.
- Price Action: LYRA shares are up 26.2% at $5.45 during the market session on the last check Friday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Lyra Therapeutics Stock Surges On Equity Raise Of $100M
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks